Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) will be reporting earnings tomorrow after market ...

Return on Assets (ROA): Supernus Pharmaceuticals's financial strength is reflected in its exceptional ROA, which exceeds ...

Supernus' reliance on Qelbree is increasing, but generic competition for other drugs poses challenges. Read why I downgrade ...

In this article, we are going to take a look at where Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) stands against other best pharma stocks to buy for long term growth. With big American ...

Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside ...

In a report released today, Stacy Ku from TD Cowen maintained a Buy rating on Supernus Pharmaceuticals (SUPN – Research Report), with a price target of $44.00. The company’s shares closed yesterday at ...

ROCKVILLE, Md., April 23, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...